<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week's podcast, &lt;em&gt;Neurology Today&lt;/em&gt;'s editor-in-chief highlights articles on the newly approved drug for neurofibromatosis 1 with plexiform neuromas in adults, how neurology practices are integrating with multiple subspecialties, and the impact of federal cuts to DEI grants and research.&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

New approved drug for neurofibromatosis 1 with plexiform neurofibromas, multidisciplinary clinics in neurology, impact of cuts to DEI research grants

APR 3, 20254 MIN
Neurology Today in 5

New approved drug for neurofibromatosis 1 with plexiform neurofibromas, multidisciplinary clinics in neurology, impact of cuts to DEI research grants

APR 3, 20254 MIN

Description

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the newly approved drug for neurofibromatosis 1 with plexiform neuromas in adults, how neurology practices are integrating with multiple subspecialties, and the impact of federal cuts to DEI grants and research.